Skip to content

Embecta Corp. EMBC EPS (Diluted)

EPS (Diluted) at other companies

Insulet logo
InsuletPODD
$1.30+160%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$0.30+84.8%
Medtronic logo
MedtronicMDT
$0.97+18.3%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$0.43-1,333%
Mannkind logo
MannkindMNKD
-$0.05-225%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
-$0.49+47.3%

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s EPS (diluted)?
Embecta Corp. (EMBC) reported EPS (diluted) of -$0.07 in Q1 2026.
How has Embecta Corp.'s EPS (diluted) changed year-over-year?
Embecta Corp.'s EPS (diluted) decreased by 117.5% year-over-year, from $0.40 to -$0.07.
What is the long-term trend for Embecta Corp.'s EPS (diluted)?
Over 4 years (2021 to 2025), Embecta Corp.'s EPS (diluted) has grown at a -31.3% compound annual growth rate (CAGR), from $7.28 to $1.62.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.